Key Points
(i) What is already known about the topic?
• Mother's preferences and willingness-to-pay (WTP) for human papillomavirus (HPV) vaccines are specific to culture and socio-economic status.
• HPV vaccines have not been integrated into Hong Kong government's immunisation schedule whilst the uptake rates amongst adolescent girls was 2.4% in 2008 and 9.1% in 2012.
(ii) What does the paper add to existing knowledge?
• This study provides new data on how HPV vaccine features are viewed and valued by mothers, by measuring how much benefit that mothers are perceived for ideal and current vaccine technologies.
• Side-effects, protection against cervical cancer, protection duration, and out-of-pocket cost determined the decision to receive or not receive the vaccine.
• The demand for HPV vaccines is high as indicated by maximum WTP but WTP for current vaccines is relatively lower than current market price, except for those who had a monthly household income of >HK$100,000 (US$12,821).
(iii) What insights does the paper provide for informing health care-related decision making?
• These findings would contribute to policy makings for the improvement of HPV vaccine uptake and inform the immunization service in Hong Kong.
• Subsidy or co-payment from government should be considered for the unmet demand of HPV vaccination.
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Cervical cancer was the eighth most common cancer among females in Hong Kong in 2014, 32 accounting for about 3.3% of all new cancer cases in females(1). In the most recent cancer 33 registry conducted in Hong Kong, there were 472 cases of cervical cancer diagnosed in 2014 34 with an age-standardised incidence rate of 8.1 per 100,000 in the population. In the past two 35 decades, burden of the disease is relatively higher compared to other developed countries(2), 36 although both the incidence and mortality rates of cervical cancer show a decreasing trend(1). 37
38
To further reduce the burden of cervical cancer, a cervical cancer screening program was 39 organised and launched in 2004(3) and two preventive vaccines were introduced and became 40 available for females in the community since 2006(4). The two commercially-available vaccines 41 offer about 70% protection against various strains of the human papillomavirus (HPV)(5), which 42 causes cervical carcinoma(6). However, HPV vaccines have yet to be integrated into the 43 government's immunisation schedule in Hong Kong(7). Instead, people voluntarily can seek the 44 vaccine in private clinics with the administration rate for adolescent girls being as low as 2.4% 45 in 2008 and 9.1% in 2012 due to lack of HPV vaccination program currently organised (4, 8) . 46
However, including the HPV vaccination for girls aged from 12 years old and upwards is 47 considered a cost-effective option compared to only offering cervical cancer screening (9, 10). 48
49
The success of the HPV vaccination program largely depends on the attitude of local 50 stakeholders towards the risks and benefits of the vaccination (11-13). For the purpose of policy 51 decision-making and improving health services, it is important to understand the various factors 52 that may affect consumer's demand and their decision towards administering the vaccine. 53
Factors associated with decision-making not only include the results of economic evaluation but 54 also other considerations such as consumer's demand and preference. With regards to the HPV 55 vaccination, mothers, who are highly involved in the decision to vaccinate or not vaccinate their 56 daughters aged under 18 years old (14, 15), were therefore regarded as the critical consumer of 57 the HPV vaccination. This study adopted a discrete choice experiment (DCE) to determine 58 consumer preference of the HPV vaccine attributes and their willingness-to-pay (WTP) for the 59 vaccine in Hong Kong. Similar studies have been conducted in other countries (16) (17) (18) (19) (20) , however 60
given that consumer preference may be subject to cultural differences, the applicability of 61 research from overseas to the local community may be limited. The aim of this study is toparticipants a range of the best and worst levels in our experimental design. All levels of each 97 shortlisted attribute were selected based on the overseas DCE studies (16) (17) (18) . Therefore, the 98 identification of the four attributes and their relevant levels were justified and supported by 99 literature review, and expert and respondent input from pilot data. The 'Protection against 100 cervical cancer' levels were expressed in percentages (50% / 70% / 80% / 100%) and presented 101 in terms of an absolute risk reduction that was mainly used for the description of risk 102 information in the DCE survey(21). The 'Protection duration' levels were expressed in years (2 / 103 5 / 10 / lifetime = 100 years). The 'Side effects' levels concern the potential side-effects 104 following administration of the HPV vaccination and were expressed in frequency (2:100 / 105 6:100 / 10:100 / 14:100). The 'Out-of-pocket cost' levels were expressed in HK dollars ($0 / 106 $1,000 / $2,000 / $3,000). 107
108

Discrete choice experimental design 109
To avoid impractically-large sample sizes, the complete set of combinations of all attribute 110 levels corresponding to a full factorial design (4*4*4*4=256 hypothetical vaccine profiles) was 111 not used in this experiment. Rather, an orthogonal design (ORTHOPLAN procedure, IBM SPSS 112
Statistics for Windows, Version 22.0) was used to produce 16 hypothetical vaccine profiles (see 113   Table 1 ) allowing the main effects to be estimated. 114
115
In our experimental design we used choice sets which contained three options: two vaccine 116 profiles and one "opt-out" option (i.e. no vaccination) (see Table 1 and 2). The "opt-out" option 117 is a realistic alternative for mothers who choose to vaccinate their daughters or not. Hence, when 118 including the "opt-out" option, respondents were not forced to choose one of the vaccine 119 profiles. 120
121
To ensure sufficient statistical efficiency by simultaneously considering respondent fatigue and 122 cognitive feasibility, each respondent was asked to treat nine choice sets with the first choice set 123 used for checking the respondents' rationality and the following eight choice sets for the 124 statistical analyses. (22, 23) . All respondents received the same nine choice sets (see Table 2 ). In 125 the first choice set, the second vaccine was better than the first vaccine with regard to protection, 126 protection duration and side effects and the second vaccine cost less than the first one (see Table  127 2). Respondents who preferred the first to the second vaccine were considered as irrational and 128 excluded from the analyses. All eight choice sets were established from achieving four desirable 129
properties (24) The experimental design consisted of eight choice set questions, each one examined by the 149 respondents, and the largest number of levels for any of the attributes was four. According to 150
Orme's rule of thumb formula(25), at least 125 participants (500 x 4 ÷ 8 ÷ 2) are required for a 151 two-alternative experimental design (the alternatives of two vaccines profiles and "no 152 vaccination" did not have varying attributes). 153
154
Statistical Analysis 155 156
The DCE choices were analysed by a multinomial logistic regression model, which regressed 157 the response to the choice question (i.e. vaccine 1, vaccine 2, or no vaccination) of the vaccine 158 attributes and levels (see Table 1 ). For 'no vaccination' which is defined as the opt-out option, 159 the levels of all attributes were all set to zero. It is assumed that there is a linearity in the levels 160 of each attribute and there is no interaction between the attributes. By adopting the linear 161 assumption, the marginal WTP would increase by the preference weight value with each 162 percentage change of protection and side effects or each year change for protection duration. 163 Therefore, the WTP could be determined by taking the ratio of the preference weight of theattribute to the preference weight of out-of-pocket cost. The marginal WTP, which represents 165 the monetary value that the participant is willing to pay for per unit for the attribute, is calculated 166 by multiplying the preference weight of the attribute with changes in levels per unit (i.e. % for 167 protection against cervical cancer and side effects or year for protection duration) as shown in 168 Equation 1. It can be derived from a specific case of the multinomial logistic regression model 169 by solving the equation for this case for marginal WTP which is that the level for the attribute in 170 question is set equal to one and the levels of all other attributes equal to zero. 171 172 The maximum WTP for development of the vaccine using ideal technology was calculated by 181 incorporating 100% protection, lifetime protection duration (i.e. 100 years), and 0% side effects 182 Sub-group analyses were conducted for different groups of education levels (Primary 1 to 6 for 196 those aged between 6-11 years old, junior secondary year 1 to 3 for those aged between 12-14years old, senior secondary year 4 to 6 for those aged between 15-17 years old, tertiary leading 198 to non-degrees and tertiary leading to degrees) and monthly household income (<HK$10,000; 199 HK10,000-20,000; HK$20,001-30,000; HK$30,001-50,000; HK$50,001-100,000; and 200 >HK$10,000). All statistical analyses were conducted using the to participate the study was 20.9% with the main reasons for refusal given as not enough time or 210 not interested in the study. Table 3 shows the respondents' characteristics and experiences in 211 relation to HPV or the HPV vaccine. The respondents had a mean age of 42.9 years, more than a 212 half were born in Hong Kong and the majority were educated to secondary level or higher. Less 213 than a half of the respondents had monthly household income more than HK$30,000. In general, 214 respondents were familiar with the vaccine. More than three-quarters of the mothers had 215 previously heard about the HPV vaccines and were concerned about their daughters' risk of 216 HPV infection and cervical cancer. However, more than a half of the mothers believed the 217 vaccines are somewhat / very unsafe and some of them refused their daughter to be 218 administered. More than 95% declared that either sex education or abstinence should be taught 219 at school. 220 221
Preferences and WTP for HPV vaccines of all respondents 222 223
In the rationality test, 11% of mothers chose no vaccination whereas 88.4% of mothers made 224 a more reasonable choice of higher protection effectiveness, longer protection duration and 225 lower out-of-pocket costs and probability of side effects. 226
227
With all the attributes treated as continuous variables in the regression, larger preference 228 weights indicate a more-preferred vaccine attribute. For a specific attribute, a positive 229 coefficient indicates that the corresponding attribute increases positivity and a higher level of 230 this attribute is preferred. This also implies that a higher level of this attribute is associatedwith a higher WTP as well as the increased likelihood to purchase. Conversely, a negative 232 coefficient indicates that the attribute generates negativity and so lower levels are preferred. 233 Table 4 shows the mothers' preferences estimated from the statistical model. All the 234 attributes have significant impact on WTP (p<0.001). Side-effects, protection against cervical 235 cancer, protection duration, and out-of-pocket cost determined the decision to receive or not 236 receive the vaccine. Our multinomial logistic regression had a pseudo R-square of 0.19612, 237 indicating marginally acceptable model fit. 238
239
The marginal WTP for each attribute and the overall WTP for the vaccine are reported in 240 Table 5 The disease burden in Hong Kong is relatively higher than that in other developed countries (1). 283
Currently, there is no universal organized vaccination program in Hong Kong while the HPV 284 vaccination among teenage girls is largely opportunistic and the reported administration rate is 285 continuously low (4, 8) . Understanding the factors that determine the administration of the HPV 286 vaccine is crucial for designing a more-effective vaccine-promotion program and for re-287 evaluating current immunisation policies. It is particularly important in the light of the recently-288 available and newly-developed 9-valent vaccine(31). As far as we are aware, this is the first 289 local study using a quantitative approach and systemic analysis to reveal consumers' preferences 290 and the WTP in relation to HPV vaccines in Hong Kong. Our study suggests that the 291 effectiveness of cervical cancer protection, the protection duration, side effects and out-of-292 pocket costs are all significant factors in the determination of whether to administer the HPV 293 vaccine. However, preferences and WTP for HPV vaccine are culture-specific and subject to 294 socio-economic status as indicated by education level and household income. 295
296
In line with the previous studies(16-19), findings from this DCE survey demonstrate that 297 'protection effectiveness' and 'protection duration' were significant attributes when making the 298 decision of whether to administer the HPV vaccination. This may be attributed to the differences 299 in culture, ethnicity and education levels in medical decision-making(32). For example, our 300 sample group from Hong Kong appears to be more conservative on sexual health issues (such as 301 believing abstinence should be taught in schools, a rate of 96.7% vs. 21.6%) and less educated 302 (tertiary level education or above, a rate of 27.5% vs. 39.7%) when compared with mothers in 303 the US(16). 304 305 According to our survey, 80% of mothers have previously heard of the HPV vaccines, and the 306 demand and conceived health benefits/risks from HPV vaccines are high as indicated by the 307 maximum WTP. In the main and sub-group analyses, mothers' maximum WTP was consistently 308 beyond the market price for the currently-available vaccine, regardless of their education and 309 income levels. The value of the HPV vaccination might reflect the fear of cervical cancer, in part 310 contributed by health education and marketing for HPV vaccinations and cervical cancer 311 prevention from diverse sectors in the recent years(33). On the other hand, the overall WTP for 312 vaccines currently offered is still lower than the market price (HK$4,500) except for those with 313 monthly household income of >HK$100,000 (HK$5,885). Subsidised or part-payment from the 314 government should be considered for to help meet the demand for the HPV vaccination, similar 315 to that of the Childhood Influenza Vaccination Subsidy Scheme(34) which encourages parents 316 of children aged between 6 months and 6 years to let their children receive influenza 317 vaccinations in private clinics. Nevertheless, the WTP for current vaccines (HK$1,620) is likely 318 to be underestimated due to its 70% effectiveness against cervical cancer, 10-year protection 319 duration and 10% of all side effects based on literature. With the launch of the 9-valent HPV 320 vaccine and a longer follow-up period being offered, the WTP for vaccines is expected to 321 increase, and subsequently, the effectiveness and protection duration will also increase. 
